| Literature DB >> 34463284 |
Frédéric Dezoteux1, Baptiste Mille2, Charlotte Fievet2, Anne-Sophie Moreau3, Alain Duhamel4, Elodie Drumez4, Daniel Mathieu3, Julien Poissy3, Delphine Staumont-Salle1, Sébastien Buche2.
Abstract
Various skin manifestations have been reported during the coronavirus disease 2019 (COVID-19) pandemic. Among these are acral vascular skin lesions in non-severe patients, but few studies have focused specifically on patients with severe COVID-19 admitted to the intensive care unit (ICU) We aimed to assess the frequency of acral vascular skin manifestations (AVSM) in patients admitted to the ICU based on systematic dermatological examination We conducted a clinical, observational and prospective study in the ICU of Lille University Hospital (France). All adult patients with RT-PCR-confirmed severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) infection were included on May 5th and 6th, 2020 A total of 39 patients with severe COVID-19 were examined (34 males and five females; median age: 61 [55-59]). We observed AVSM in 11/39 patients (28%) including five with acral necrotic lesions, three with haemorrhagic blisters, one with acral livedoid rash, and one with erosive distal lesions. Chilblain or chilblain-like lesions were not seen, unlike ambulatory or non-severe patients described in the literature. There was no difference regarding the median length of stay in the ICU, initial symptoms of COVID-19 or baseline characteristics, except for a lower BMI in patients with AVSM. All patients had biological coagulation abnormalities (e.g. higher levels of fibrinogen or D-dimers), but there was no difference between patients with and without AVSM AVSM are infrequent and heterogenous and seem to be non-specific to patients with severe SARS-CoV-2, and possibly unrelated to COVID-19. The pathophysiology of AVSM described during the COVID-19 pandemic is not fully elucidated.Entities:
Keywords: COVID-19; SARS-CoV-2; chilblain; coronavirus; intensive care unit; vascular skin manifestations
Year: 2021 PMID: 34463284 PMCID: PMC8572689 DOI: 10.1684/ejd.2021.4107
Source DB: PubMed Journal: Eur J Dermatol ISSN: 1167-1122 Impact factor: 2.805